Cargando…
Highly variable pharmacokinetics of dexmedetomidine during intensive care: a case report
INTRODUCTION: Dexmedetomidine is a selective and potent alpha2-adrenoceptor agonist licensed for use in the sedation of patients initially ventilated in intensive care units at a maximum dose rate of 0.7 μg/kg/h administered for up to 24 hours. Higher dose rates and longer infusion periods are somet...
Autores principales: | Iirola, Timo, Laitio, Ruut, Kentala, Erkki, Aantaa, Riku, Kurvinen, Juha-Pekka, Scheinin, Mika, Olkkola, Klaus T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848065/ https://www.ncbi.nlm.nih.gov/pubmed/20184754 http://dx.doi.org/10.1186/1752-1947-4-73 |
Ejemplares similares
-
Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients
por: Iirola, Timo, et al.
Publicado: (2011) -
Pharmacokinetics of long-lasting, high-dose dexmedetomidine infusions in critically ill patients
por: Iirola, T, et al.
Publicado: (2011) -
Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study
por: Leino, Kari, et al.
Publicado: (2011) -
Predictive equations over-estimate the resting energy expenditure in amyotrophic lateral sclerosis patients who are dependent on invasive ventilation support
por: Siirala, Waltteri, et al.
Publicado: (2010) -
Is the effect of non-invasive ventilation on survival in amyotrophic lateral sclerosis age-dependent?
por: Siirala, Waltteri, et al.
Publicado: (2013)